Clinical Trials
5 trialsNCT07617337 2026-06-01
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
Chugai Pharmaceutical
Phase 1 Not yet recruiting
NCT07556549 2026-05-22
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
Active not recruiting
NCT05297890 2026-05-19
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting
NCT07567352 2026-05-12
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
Active not recruiting
NCT07415005 2026-05-05
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting